Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ultra-deep sequencing data from a liquid biopsy proficiency study demonstrating analytic validity.

Scientific data - 13 Apr 2022

Gong Binsheng, Deveson Ira W, Mercer Timothy, Johann Donald J, Jones Wendell, Tong Weida, Xu Joshua

Abstract excerpt

Recently we reported the accuracy and reproducibility of circulating tumor DNA (ctDNA) assays using a unique set of reference materials, associated analytical framework, and suggested best practices. With the rapid adoption of ctDNA sequencing in precision oncology, it is critical to understand the analytical validity and technical limitations of this cutting-edge and medical-practice-changing technology. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Circulating Tumor DNA

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to High-Throughput Nucleotide Sequencing

Share to Liquid Biopsy

Share to Mutation

Share to Neoplasms

Share to Precision Medicine

Share to Reproducibility of Results

Source

Open in PubMed Open full text

Identifiers

PMID: 35418127
DOI: 10.1038/s41597-022-01276-8
PMCID: PMC9008010

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ultra-deep sequencing data from a liquid biopsy proficiency study demonstrating analytic validity.PMID 35418127Read ↗

Analytical and Clinical Validation of Cell-Free Circulating Tumor DNA Assay for the Estimation of Tumor Mutational Burden.Semantic proximity Read ↗

Reliability of liquid biopsy analysis: an inter-laboratory comparison of circulating tumor DNA extraction and sequencing with different platformsSemantic proximity Read ↗

Analytical performance evaluation of a commercial next generation sequencing liquid biopsy platform using plasma ctDNA, reference standards, and synthetic serial dilution samples derived from normal plasma.Semantic proximity Read ↗

A clinician's handbook for using ctDNA throughout the patient journey.Semantic proximity Read ↗

Advancing Evidence Generation for Circulating Tumor DNA: Lessons Learned from A Multi-Assay Study of Baseline Circulating Tumor DNA Levels across Cancer Types and StagesSemantic proximity Read ↗

Analytical evaluation of circulating tumor DNA sequencing assays.Semantic proximity Read ↗

Current practices and guidelines for clinical next-generation sequencing oncology testing.Semantic proximity Read ↗

Implementation of circulating tumour DNA multi-target mutation testing in plasma: a perspective from an external quality assessment providers' survey.Semantic proximity Read ↗

Liquid biopsies across the cancer care continuum.Semantic proximity Read ↗

Next-Generation Sequencing Concordance Analysis of Comprehensive Solid Tumor Profiling between a Centralized Specialty Laboratory and the Decentralized Personal Genome Diagnostics elio Tissue Complete Kitted Solution.Semantic proximity Read ↗

Reporting of molecular test results from cell-free DNA analyses: expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA WorkshopSemantic proximity Read ↗

Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNASemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.